Literature DB >> 32357266

Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease.

Etienne C Hirsch1, David G Standaert2.   

Abstract

Parkinson's disease is a progressive and debilitating disorder that has so far eluded attempts to develop disease-modifying treatment. Both epidemiological and genetic studies support a role of neuroinflammation in the pathophysiology of Parkinson's disease. Postmortem studies and experimental analyses suggest the involvement of both innate and adaptive immunity in the degenerative process. There is also some circumstantial evidence for effects of immune therapies on the disease. In the present article, we review 10 unanswered questions related to neuroinflammatory processes in Parkinson's disease with the goal of stimulating research in the field and accelerating the clinical development of neuroprotective therapies based on anti-inflammatory strategies.
© 2020 International Parkinson and Movement Disorder Society. © 2020 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  lymphocytes; microglial cells; neurodegeneration; α-synuclein

Mesh:

Substances:

Year:  2020        PMID: 32357266     DOI: 10.1002/mds.28075

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  42 in total

Review 1.  Exploring the Role of Ubiquitin-Proteasome System in Parkinson's Disease.

Authors:  Tapan Behl; Sachin Kumar; Ziyad M Althafar; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Vishnu Nayak Badavath; Shivam Yadav; Saurabh Bhatia; Ahmed Al-Harrasi; Yosif Almoshari; Mohannad A Almikhlafi; Simona Bungau
Journal:  Mol Neurobiol       Date:  2022-05-03       Impact factor: 5.590

2.  Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson's disease.

Authors:  Bing Cao; Yanqiu Zhang; Jinhu Chen; Pengyue Wu; Yuxuan Dong; Yanqin Wang
Journal:  Metab Brain Dis       Date:  2021-11-24       Impact factor: 3.584

Review 3.  Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside.

Authors:  Awanish Mishra; Ritam Bandopadhyay; Prabhakar Kumar Singh; Pragya Shakti Mishra; Neha Sharma; Navneet Khurana
Journal:  Metab Brain Dis       Date:  2021-08-13       Impact factor: 3.584

Review 4.  Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.

Authors:  Elizabeth M Kline; Madelyn C Houser; Mary K Herrick; Philip Seibler; Christine Klein; Andrew West; Malú G Tansey
Journal:  Mov Disord       Date:  2020-12-14       Impact factor: 10.338

Review 5.  Perspective: Treatment for Disease Modification in Chronic Neurodegeneration.

Authors:  Thomas Müller; Bernhard Klaus Mueller; Peter Riederer
Journal:  Cells       Date:  2021-04-12       Impact factor: 6.600

6.  Alteration in the Cerebrospinal Fluid Lipidome in Parkinson's Disease: A Post-Mortem Pilot Study.

Authors:  Joaquín Fernández-Irigoyen; Paz Cartas-Cejudo; Marta Iruarrizaga-Lejarreta; Enrique Santamaría
Journal:  Biomedicines       Date:  2021-04-29

Review 7.  Possible Link between SARS-CoV-2 Infection and Parkinson's Disease: The Role of Toll-Like Receptor 4.

Authors:  Carmela Conte
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

Review 8.  The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline.

Authors:  Per Borghammer
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

9.  Decreased Risk of Parkinson's Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls.

Authors:  Jonas Bacelis; Michele Compagno; Sonia George; J Andrew Pospisilik; Patrik Brundin; Åsa Torinsson Naluai; Lena Brundin
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

Review 10.  View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson's Disease: Are We on the Right Track?

Authors:  Thomas Müller
Journal:  Biologics       Date:  2021-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.